AWS AppFabric quickly connects SaaS applications for better productivity and security

November 09, 2023 09:00 AM Eastern Standard Time
BOSTON--(BUSINESS WIRE)--NetWitness, a globally trusted provider of threat detection, investigation, and response technology and incident response services, today announced it is now integrated with AWS AppFabric, a new service from Amazon Web Services (AWS) that quickly connects software as a service (SaaS) applications for better productivity and security.

“Throughout our journey, NetWitness has been at the forefront of expanding visibility into emerging technologies and innovative solutions”

Integrating security solutions with SaaS apps can be a time-consuming and error-prone task. Each integration requires custom development, deployment, security measures, and ongoing maintenance. However, AWS AppFabric offers a streamlined solution by providing a ... Read more »

 

(BUSINESS WIRE) -- American Tower Corporation's Africa operations (ATC Africa, or the Company), and MTN Nigeria, today announced that they have entered into a new agreement that is expected to enhance wireless connectivity across Nigeria.

 

Under the terms of the agreement, ATC Africa will facilitate new tenancies for MTN Nigeria over a multi-year period, commencing in the second half of 2024. The Company expects to meet MTN Nigeria's site requirements by leveraging ATC Africa's extensive portfolio of over 8,000 sites in Nigeria, a substantial portion of which already incorporate green energy solutions. Additionally, new sites will be deployed in accordance with ATC Africa's green site specifications.

 

Marek Busfy, Senior Vice President and CEO of ATC Africa expres ... Read more »

cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening Acute Events and Debilitating Chronic Symptoms
Takeda Continues 70-plus Year Legacy of Driving Innovation for the Rare Hematology Community
 

(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ADZYNMA (ADAMTS13, recombinant-krhn) for the prophylactic and on-demand treatment of adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). ADZYNMA is the first and only FDA-approved recombinant ADAMTS13 (rADAMTS13) protein designed to address an unmet medical need in people with cTTP by replacing the deficient ADAMTS13 enzyme.1,2

“People living with cTTP face serious, life-threatening health challenges, and until today, were without any approved treatment specifically indicated for their disease,” said Julie Kim, president, U.S. Business Unit and U.S. country head at ... Read more »

Group Affirms Full-year Outlook

(BUSINESS WIRE) -- November 10, 2023

3Q 2023:

Total business volume increases 4.5 percent to 36.5 billion euros

Operating profit softens by 14.6 percent to 3.5 billion euros; driven by the Property-Casualty business segment affected by a 7.3 percentage point impact by natural catastrophes on the combined ratio, the highest in a decade

Shareholders’ core net income 2.1 billion euros, down by 29.3 percent

9M 2023:

Total business volume rises 4.7 percent to 122.1 billion euros

Operating profit increases 3.6 percent to 11.0 billion euros: primarily driven by the Life/Health business segment

Shareholders’ core net income 6.8 billion euros, up by 25.5 percent

Further improved Solvency II capitalization ratio of 212 percent, compared with 201 percent at the end of 4Q 20221

Outlook:

2023 operating profit target confirmed at 14.2 billion euros, plus or m ... Read more »